Answers are grounded in this paper and cite their sources.
Introduction BTK inhibitors have transformed the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), but strategies to deepen and prolong response are needed. Lenalidomide is active in CLL/SLL through a non‐overlapping mechanism but is limited by toxicity. We evaluated lenalidomide combined with ibrutinib in relapsed/refractory (R/R) CLL/SLL. Methods In this multicenter, phase 1, 3+3 dose‐escalation study, patients with R/R CLL/SLL after ≥ 1 prior therapy received a 28‐day ibrutinib run‐in (420 mg daily), then added lenalidomide with intra‐patient escalation to a cohort‐assigned maximum of 2.5, 5, 7.5, or 10 mg daily. Lenalidomide was stopped after 12 cycles; ibrutinib continued until progression or intolerance. The primary endpoint was safety, tolerability, and maximum tolerated dose (MTD). Results Twenty‐seven patients were enrolled. The MTD of lenalidomide was 5 mg daily. Dose interruptions or reductions occurred in 85% of patients; 7 (26%) and 5 (19%) discontinued for toxicity and progression, respectively. Significant cardiac toxicity occurred in 26%, including heart failure and ventricular arrhythmia (2 patients [7%] each). The overall response rate was 88% (13% complete response). After a median follow‐up of 50.4 months, median progression‐free survival was 69.5 months (95% CI 53.4–NE). Conclusion Lenalidomide plus ibrutinib is effective in R/R CLL/SLL but carries an unexpectedly high risk of cardiac toxicity. Trial Registration ClinicalTrials.gov identifier: NCT01886859
No takes yet. Share an insight, caveat, or question.
Bair et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: